Patents by Inventor Glenn Meyer

Glenn Meyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Controlled Release Dosage Form
    Publication number: 20200188341
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Application
    Filed: February 24, 2020
    Publication date: June 18, 2020
    Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20200129454
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 31, 2019
    Publication date: April 30, 2020
    Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
  • Controlled Release Dosage Form with Enhanced Pharmacokinetics
    Publication number: 20200129439
    Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Application
    Filed: December 31, 2019
    Publication date: April 30, 2020
    Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Claude E. WRIGHT
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20200129455
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 31, 2019
    Publication date: April 30, 2020
    Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
  • Controlled release dosage form
    Patent number: 10610505
    Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: April 7, 2020
    Assignee: Osmotica Kereskedelmi ES Szolgaltato KFT
    Inventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
  • Controlled release dosage form with enhanced pharmacokinetics
    Patent number: 10532031
    Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: January 14, 2020
    Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Claude E. Wright
  • Composition and method for treating neurological disease
    Patent number: 10512617
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: December 24, 2019
    Assignee: Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelösségû Társaság
    Inventors: Glenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo
  • Composition and method for treating neurological disease
    Patent number: 10500170
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: December 10, 2019
    Assignee: Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság
    Inventors: Glenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo
  • Composition and method for treating neurological disease
    Patent number: 10500172
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: December 10, 2019
    Assignee: Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság
    Inventors: Glenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo
  • Composition and method for treating neurological disease
    Patent number: 10500171
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: December 10, 2019
    Assignee: Osmotica Kereskedelmi és SzolgáltatóKorlátolt Felelõsségû Társaság
    Inventors: Glenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo
  • Controlled release dosage form
    Patent number: 10471031
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: November 12, 2019
    Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
  • Controlled Release Dosage Form
    Publication number: 20190255005
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Application
    Filed: April 10, 2019
    Publication date: August 22, 2019
    Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20190247329
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 17, 2019
    Publication date: August 15, 2019
    Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20190247327
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 7, 2019
    Publication date: August 15, 2019
    Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20190247328
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 7, 2019
    Publication date: August 15, 2019
    Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20190247331
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 5, 2019
    Publication date: August 15, 2019
    Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20190247330
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 17, 2019
    Publication date: August 15, 2019
    Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
  • Controlled Release Dosage Form
    Publication number: 20190167618
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 6, 2019
    Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
  • Controlled release dosage form
    Patent number: 10300032
    Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: May 28, 2019
    Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
  • Controlled Release Dosage Form
    Publication number: 20190111013
    Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 18, 2019
    Applicant: Osmotica Kereskedelmi ES Szolgaltato KFT
    Inventors: Glenn A. MEYER, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright